Long-Term Preclinical Magnetic Resonance Imaging Alterations in Sporadic Creutzfeldt-Jakob Disease
Ann Neurol 80:629-632, Zanusso, G.,et al, 2016
Prodromal Symptoms of Multiple Sclerosis in Primary Care
Ann Neurol 83:1162-1173, Disanto,G.,et al, 2018
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Fat Embolism Syndrome Secondary to Bone Marrow Necrosis in Patients with Hemoglobinopathies
SMJ 109:549-553, Gangaraju, R.,et al, 2016
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Prodromal Alzheimers Disease: Successive Emergence of the Clinical Symptoms
Ann Neurol 64:492-498,479, Amieva,H.,et al, 2008
Predictors of Diagnosis in Huntington Disease
Neurol 68:1710-1717, Langbehn,D.R.,et al, 2007
Psychiatric Disorders in Preclinical Huntingtons Disease
JNNP 78:939-943, Julien,C.L.,et al, 2007
Clinical Presentation and Pre-Mortem Diagnosis of Variant Creutzfeldt-Jakob Disease Associated With Blood Transfusion: A Case Report
Lancet 368:2061-2067, Wroe,S.J.,et al, 2006
A 32-Year Prospective Study of Change in Body Weight and Incident Dementia
Arch Neurol 62:55-60,20, Stewart,R.,et al, 2005
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Functional Deficits in Patients with Mild Cognitive Impairment
Neurol 58:758-764, Tabert,M.H.,et al, 2002
Incidence and Outcome of Mild Cognitive Impairment in a Population-Based Prospective Cohort
Neurol 59;1594-1599, Larrieu,S.,et al, 2002
Early Detection of Dementia: Mild Cognitive Impairment (an Evidence-based Review)
Neurol 56:1133-1142, 1131, Petersen,R.C.,et al, 2001
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Might Olfactory Dysfunction be a Marker of Early Alzheimer's Disease?
Lancet 355:84-85, Burns,A., 2000
The Preclinical Phase of Alzheimer Disease
Arch Neurol 57:808-813, Elias,M.F.,et al, 2000
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
NEJM 343:450-456,502, Bookheimer,S.Y. et al, 2000
The Value of Informant Versus Individual's Complaints of Memory Impairment in Early Dementia
Neurol 55:1724-1726, Carr,D.B.,et al, 2000
Serial Magnetic Resonance Imaging of Cerebral Atrophy in Preclinical Alzheimer's Disease
Lancet 353:2125, Fox,N.C.,et al, 1999
Preclinical Prediction of Alzheimer's Disease Using SPECT
Neurol 50:1563-1571, Johnson,K.A.,et al, 1998
Few Psychological Consequences of Presymptomatic Testing for Huntington Disease
Lancet 349:4, Bundey,S., 1997
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the e4Allele for Apolipoprotein E
NEJM 334:752-758, 7911996., Reiman,E.M.,et al, 1996
Neuropsychological Detection and Characterization of Preclinical Alzheimer's Disease
Neurol 45:957-962, Jacobs,D.M.,et al, 1995